Discover how breakthroughs in stem cell science are shaping the future of central nervous system (CNS) therapeutics. In this on-demand webinar, Dr. Thomas Hartung of Johns Hopkins Bloomberg School of Public Health explores the promise and complexity of using stem cells—particularly iPSC-derived organoid models—to regenerate damaged areas of the central nervous system.
With limited natural regeneration in the CNS, patients face irreversible impairments from injury and disease. But organoid technologies now offer a powerful way to model human brain environments, bringing us closer to precision medicine and effective treatments. Learn how these models are driving preclinical research forward, uncovering mechanisms of action, and opening new paths to clinical application.
Dr. Thomas Hartung is a globally recognized expert in toxicology, stem cell biology, and alternatives to animal testing. He serves as Professor of Environmental Health and Engineering at the Johns Hopkins Bloomberg School of Public Health, where he also directs the Center for Alternatives to Animal Testing (CAAT).
With a dual background in medicine and neuroscience, Dr. Hartung’s research bridges basic science and public health innovation. His work has led to major advances in the development of human-relevant, non-animal testing methods, including the use of induced pluripotent stem cell (iPSC)-derived brain organoids to model neurological disease and assess neurotoxicity.
Prior to joining Johns Hopkins, Dr. Hartung was the Head of the European Centre for the Validation of Alternative Methods (ECVAM) and has contributed extensively to international efforts shaping regulatory science and human-centric research. He is a prolific author and speaker, and a leading advocate for ethical, effective, and innovative approaches to biomedical research.
